1. Medtech Insight
  2. >>Policy & Regulation

Market Intel: Unravelling Bundled Payments: A New Chapter In Reimbursement For Orthopedics

 
• By Marion Webb

The shift in health care reimbursement from a fee-for-service model to one which is based on value and an emphasis on accountability for care quality and health care costs is here to stay. In orthopedics, as in other therapy sectors, physicians are having to grapple with new alternative payment models and meeting the requirements that come with these new reimbursement methods. Strategies for adopting these value-based systems, including challenges and trends, and what it all means for surgeons, dominated much of the discussion at this year's American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego.

Doctor holding out your piggy bank wanting payment/ Your Savings To Pay Bill, insert coins to it,Stethoscope financial checkup or saving for medical insurance costs money plan fee Lifestyle concept
• Source: shutterstock.com

After the US Centers for Medicare and Medicaid Services took the lead in developing new payment models, such as the Medicare Bundled Payment for Care Improvement (BPCI) and Comprehensive Care for Joint Replacement (CJR) programs, many health care provider organizations in the country have made the transition to these alternative payment systems. At this year's annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) in San Diego, one of the key takeaways for attending surgeons was how they could implement strategies to meet the March 2018 deadline for submitting some type of performance year data to CMS in order to avoid penalties in income starting in 2019.

This article highlights presentations and discussions from the viewpoint of orthopedic surgeons including: what to expect from the different Medicare bundled payment models, the challenges and new developments; what it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 
• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

More from Medtech Insight

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.